Initiation of adjuvant hormone therapy by medicaid insured women with nonmetastatic breast cancer

Journal of the National Cancer Institute

Volumn 104, Issue 14, 2012, Pages 1102-1105

  Yung, Rachel L ^a   Hassett, Michael J ^a   Chen, Kun ^a   Gesten, Foster C ^a   Roohan, Patrick J ^a   Boscoe, Francis P ^a   Sinclair, Amber H ^a   Schymura, Maria J ^a   Schrag, Deborah ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; COMORBIDITY; CONFIDENCE INTERVAL; FEMALE; HIGH RISK PATIENT; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; MEDICAID; MEDICAL EDUCATION; MENTAL HEALTH; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PARTIAL MASTECTOMY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RACE; RISK;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BENCHMARKING; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LOGISTIC MODELS; MEDICAID; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ODDS RATIO; UNITED STATES;

EID: 84864452219     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs273     Document Type: Article

References (35)

1. Cancer Statistics. Surveillance, Epidemiology, and End Results. http://seer.cancer.gov/statistics/. Accessed March 15, 2011.
2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
3. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer 2011, version 2.2011. http://www.nccn.org/professionals/physician- gls/pdf/breast.pdf. Accessed June 8, 2011.
4. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28(23):3784-3796.
5. T he Quality Oncology Practice Initiative Summary of Fall 2011 measures. 2011; http://qopi.asco.org/Documents/QOPI Fall2011MeasuresSummary.pdf. Accessed November 4, 2011.
6. Bickell NA, Wang JJ, Oluwole S, et al. Missed opportunities: Racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006;24(9):1357-1362.
7. Freedman RA, Virgo KS, He Y, et al. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011;117(1):180-189.
8. H ershman DL, Unger JM, Barlow WE, et al. Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol. 2009;27(13):2157-2162.
9. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Research and Treatment. 2003;81(1):21-31.
10. Ansell D, Whitman S, Lipton R, Cooper R. Race, income, and survival from breast cancer at two public hospitals. Cancer. 1993;72(10):2974-2978.
11. Bassett MT, Krieger N. Social class and black-white differences in breast cancer survival. American Journal of Public Health. 1986;76(12):1400-1403.
12. Lannin DR, Mathews HF, Mitchell J, Swanson MS, Swanson FH, Edwards MS. Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA. 1998;279(22):1801-1807.
13. Sprague BL, Trentham-Dietz A, Gangnon RE, et al. Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer. 2011;117(7):1542-1551.
14. Y u XQ. Socioeconomic disparities in breast cancer survival: Relation to stage at diagnosis, treatment and race. BMC Cancer. 2009;9:364.
15. Iezzoni LI, Ngo LH, Li D, Roetzheim RG, Drews RE, McCarthy EP. Early stage breast cancer treatments for younger Medicare beneficiaries with different disabilities. Health Services Research. 2008;43(5p1):1752-1767.
16. M cCarthy EP, Ngo LH, Roetzheim RG, et al. Disparities in breast cancer treatment and survival for women with disabilities. Annals of Internal Medicine. 2006;145(9):637-645.
17. Goodwin JS, Zhang DD, Ostir GV. Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. Journal of the American Geriatrics Society. 2004;52(1):106-111.
18. T he Kaiser Family Foundation Statehealthfacts. org Datasource http://pdf.kff.org/mfs/NYUS. pdf and http://pdf.kff.org/mfs/CAUS.pdf. 2011; http://www.statehealthfacts.org/profileglance. jsp?rgn=6&rgn=34. Accessed June 8, 2011.
19. Freedman RA, He Y, Winer EP, Keating NL. Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol. 2009;27(5):713-719.
20. H ershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120-4128.
21. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, lowincome women with breast cancer. J Clin Oncol. 2009;27(21):3445-3451.
22. Boscoe FP, Schrag D, Chen K, Roohan PJ, Schymura MJ. Building capacity to assess cancer care in the Medicaid population in New York State. Health Services Research. 2011;46(3):805-820.
23. NYS Cancer Registry and Cancer Statistics Datasource. http://www.nyhealth.gov/statistics/cancer/registry/. [Webpage]. 2010; http://www.nyhealth.gov/statistics/cancer/registry/. Accessed February 14, 2011.
24. M edicaid. Centers for Medicare and Medicaid Services 2011; http://www.cms.gov/Medicaid GenInfo/. Accessed March 14, 2011.
25. Administration UFaD. FDA National Drug Code Directory. http://www.accessdata.fda. gov/scripts/cder/ndc/default.cfm. Accessed December, 2010.
26. Partridge AH, Archer L, Kornblith AB, et al. Adherence and persistence with oral adjuvant chemotherapy in older women with earlystage breast cancer in CALGB 49907: Adherence companion study 60104. J Clin Oncol. 2010;28(14):2418- 2422.
27. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26(4):556-562.
28. Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Research and Treatment. 2011;125(1):191-200.
29. Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol. 2009;20(3):431-436.
30. Svahn TH, Niland JC, Carlson RW, et al. Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer. J Natl Compr Canc Netw. 2009;7(2):115-121.
31. Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. The New England Journal of Medicine. 1993;329(5):326-331.
32. Bradley CJ, Gardiner J, Given CW, Roberts C. Cancer, Medicaid enrollment, and survival disparities. Cancer. 2005;103(8):1712-1718.
33. Bradley CJ, Given CW, Roberts C. Disparities in cancer diagnosis and survival. Cancer. 2001;91(1):178-188.
34. M cDavid K, Tucker TC, Sloggett A, Coleman MP. Cancer survival in Kentucky and health insurance coverage. Archives of Internal Medicine. 2003;163(18):2135-2144.
35. Komenaka IK, Martinez ME, Pennington RE, Jr., et al. Race and ethnicity and breast cancer outcomes in an underinsured population. Journal of the National Cancer Institute. 2010; 102(15):1178-1187.